{"organizations": ["GSK"], "uuid": "724bbe005ef1ed983f78e5623f6cb32c3d057244", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "uk.finance.yahoo.com", "main_image": "https://s1.yimg.com/bt/api/res/1.2/M7vS95b2fvSzHFeFStPk0A--/YXBwaWQ9eW5ld3NfbGVnbztxPTc1O3c9NjAw/http://l.yimg.com/os/mit/media/m/social/images/social_default_logo-1481777.png", "site_section": "https://uk.finance.yahoo.com/news/sector-health-care/?format=rss", "section_title": "Health Care News | Pharmaceutical News - Yahoo! Finance UK", "url": "https://uk.finance.yahoo.com/news/gsk-profile-class-antibiotic-nov-205645304.html", "country": "US", "title": "GSK to profile new class of antibiotic at Nov. 3 investor day", "performance_score": 0, "site": "yahoo.com", "participants_count": 0, "title_full": "GSK to profile new class of antibiotic at Nov. 3 investor day", "spam_score": 0.0, "site_type": "news", "published": "2015-10-22T23:56:00.000+03:00", "replies_count": 0, "uuid": "724bbe005ef1ed983f78e5623f6cb32c3d057244"}, "author": "", "url": "https://uk.finance.yahoo.com/news/gsk-profile-class-antibiotic-nov-205645304.html", "ord_in_thread": 0, "title": "GSK to profile new class of antibiotic at Nov. 3 investor day", "locations": [], "entities": {"persons": [], "locations": [], "organizations": []}, "highlightText": "", "language": "english", "persons": [], "text": "Tip : Use comma (,) to separate multiple quotes. Learn more... \nFri, Oct 23, 2015, 07:05 BST - UK Markets open in 55 mins. GSK to profile new class of antibiotic at Nov. 3 investor day Reuters - UK Focus â€“ 9 hours ago 20.86 +0.71 \nLONDON, Oct (HKSE: 3366-OL.HK - news ) 22 (Reuters) - British pharmaceutical company GlaxoSmithKline (Other OTC: GLAXF - news ) will profile its drug development pipeline, including a new class of antibiotic, on Nov. 3, its chief executive said on Thursday. \nThe event in New York - the company's first investor day centred on drug development for more than a decade - will profile medicines from a pipeline that is 80 percent first-in-class, Andrew Witty said in a public interview at the Chatham House think-tank in London. \nIt (Other OTC: ITGL - news ) will include an update on its Type 2 topoisomerase inhibitor drug candidate, which is in the Phase II stage of development, according to Witty. \nHe said that only two new classes of antibiotics - drugs which treat bacterial infections - had been discovered in the past 40 years. \"We have a third one,\" he said. \n(Reporting by Paul Sandle; Editing by Mark Heinrich)", "external_links": [], "published": "2015-10-22T23:56:00.000+03:00", "crawled": "2015-10-23T09:19:23.349+03:00", "highlightTitle": ""}